Healthcare Jan 05, 2022 04:54 PM (GMT+8) · EqualOcean
Today, the official website of China National Drug Administration (nmpa) announced that Rongchang biology's application for listing of new indications of vidicizumab for injection was approved. According to the publicity information of priority review, the drug is approved to treat specific patients with urothelial cancer this time. Vidicizumab is an antibody coupled drug (ADC) targeting HER2, which has previously been approved to treat specific gastric cancer patients in China. According to public data, devitamab vedotin (rc48) is the first ADC independently developed by a Chinese company and approved for listing. Its molecular structure includes the following three parts: 1) a new humanized HER2 antibody; 2) Connexins with cleavability in tumor cells; 3) Small molecule cytotoxic drugs with high toxicity and side killing effect. The characteristic of this therapy is that it can accurately attack cancer cells like a missile.